← Leaderboards
Diana Nora Vaz Saleiro
Northwestern University At Chicago
$1,140,596
Attributed
$1,140,596
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $408.6K · FY2020–25$500K$375K$250K$125K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,140,596 · 2
By mechanism
R01$732,000 · 1
R21$408,596 · 1
Top collaborators
No co-investigators on record.
Most similar at Northwestern University At Chicago
Same institution · by research overlap
- Liang Zhou$11,166,761
- Jacqueline Sara Jeruss$5,717,141
- Elena Montauti$146,802
- Nabil Alshurafa$5,898,734
- Christopher R. Arnette$56,829
Others in their field
Other Emerging Leaders on “In Vitro”
- Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
- Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
- Leonard Freedmand · Leidos Biomedical Research, Inc.$68,796,314
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$41,541,738
- John Damon Chodera · Sloan-Kettering Inst Can Research$34,949,884
- Tony Moody · Duke University$34,777,314
Research focus
In VitroMissionImmunosuppressionInterferon Type IiMalignant NeoplasmsMelanoma CellImmuneImmune ResponseGenesImmunotherapyIn VivoKnock-OutMediatingMelanomaAffectGenetic TranscriptionImmune Checkpoint InhibitorCoculture TechniquesGene ExpressionCombined Modality TherapyGenerationsCrispr/Cas TechnologyGeneticPathway Interactions
Grant awards (3)
A novel pathway to overcome resistance to immunotherapy in melanoma$366,000
R01 · FY2025 · CA · contact PI
A novel pathway to overcome resistance to immunotherapy in melanoma$366,000
R01 · FY2024 · CA · contact PI
A Novel ULK1 Pathway as a New Therapeutic Target in Melanoma$408,596
R21 · FY2020 · CA · contact PI